RESEARCH / PARTICIPATIONBack to the library
← Find a study
Recruiting · registry status

Understanding a brain chemical system in ageing and Parkinson’s

Researchers study the role of the noradrenaline signalling system in healthy ageing and Parkinson’s.

Testing a treatment or activity · Study reference: NCT07569120

Plain-language introduction written with AI from the registry; not independently checked by a clinician. Read the original details below ↓

Open the official registry record ↗

Follow this study

Looking for volunteers

Start (reported actual date)
2026-06-29
Main measurements finished (planned)
2029-09
Study finished (planned)
2029-09

Planned dates can move. A study finishing does not tell us when a paper will be published.

No results summary has been confirmed in the registry records we imported. See connected papers below; we keep checking after recruitment ends.

Changes we have recorded
  • 2026-10-11 — recruiting

These are dates we observed a change, not necessarily the dates it happened.

Papers connected to this study

No connected paper has been found yet. The tracker checks the growing library for study identifiers and registry-linked publications.

Who can join?

Ages 20 years to 80 years · Also accepts healthy volunteers

These are starting points, not the full rules. The research team can tell you whether the study is right for your situation.

Read all the rules for taking part

Sex eligibility reported by registry: all

Inclusion Criteria for the healthy controls: * Age between 20 years and 80 years * Weight between 40kg and 100kg * Without neurologic or psychiatric history * Without head trauma history including loss of consciousness superior to 30 minutes. * With highly effective contraception for women of childbearing age * Affiliated to a social security or similar scheme * Not subject to any legal protection measures * Participant must have signed an informed consent document Inclusion Criteria for the patients with Parkinson's disease: * Age between 40 years and 80 years * Weight between 40kg and 100kg * With an idiopathic Parkinson's disease (Dopa-sensitive) * Without head trauma history including loss of consciousness superior to 30 minutes. * Without associated neurological pathology * With highly effective contraception for women of childbearing age * Affiliated to a social security or similar scheme * Not subject to any legal protection measures * Participant must have signed an informed consent document Exclusion Criteria for all participants : * Subject receiving (or having received in the last month) somatic medication with cerebral or psychological effects (e.g., antihistamines), see list in Appendix1 * Subjects with a current or past dependence on alcohol or any other addictive substance according to DSM-IV-TR criteria, with the exception of nicotine and caffeine; - * Subjects already participating in another biomedical research project or who have participated in a study using ionizing radiation within the past year; * Pregnant woman parturient or breastfeeding * MRI contraindications (: people using pacemaker or insulin pumps, with implanted or embedded metal objects in the head or body, claustrophobic, with neurosensory stimulators or implantable defibrillators, with cochlear implants, with ferromagnetic foreign bodies in the eye or brain close to nerve structures, agitation of the subject (uncooperative or agitated subjects), ventriculoperitoneal neurosurgical shunt valves, dental appliances) * Subject with a contraindication to PET scans at the ORM: hypersensitivity to the active substance or to any of the excipients (sodium chloride) * Subjects who are unable to understand or complete the study (language barrier, obvious lack of motivation, etc.) as judged by the investigator. * Subjects who do not agree to be informed in the event of an incidental finding of an abnormality on MRI or during neuropsychological assessment. * Persons deprived of their liberty by judicial or administrative decision. * Persons receiving psychiatric care. * Persons admitted to a health or social care facility for purposes other than research.
Full study name & original research details

Official study title

Diving Into the in Vivo Noradrenergic System : Role of the alpha2C-adrenergic Receptors

Short title used by the registry

In Vivo Noradrenergic System and Aging

Original description

The main goal of this research proposal is to provide, for the first time in humans, a wider understanding of the role of the noradrenergic system both in health and illness (here Parkinson's disease) through the use of a newly developed radiotracer visualizing alpha2C-ARs (\[11C\]ORM-13070) combined with a cutting-edge technology, the hybrid PET/MRI scanner. The secondary aim will be to determine whether the expected age- and PD-related changes in the noradrenergic system are paralleled by changes in neuropsychological performances (i.e. cognitive, motor and/or olfactory abilities).

Conditions reported: Healthy Aging and Parkinson's Disease

Registry records for this study

Records are joined using registration identifiers. Titles alone do not establish that two studies are the same.

Study type
Interventional
Interventions
PET/MRI scanning session; Neuropsychological examination; Olfactory screening
Phases
NA
Sponsor
Hospices Civils de Lyon
Start date reported by registry
2026-06-29 (actual)

Registry updated: 2026-07-09 · Status last verified by the registry submitter: 2026-07

Registry records retrieved 2026-10-11 (UTC). Individual records may have older updates. Recruitment and eligibility must be confirmed with the study team.

Contact the research team

Public study contacts supplied to the registry. Ask whether recruitment is still open and what participation involves.

Chloé Laurencin, MD / PhD · 472118022 · chloe.laurencin@chu-lyon.fr

Bénédicte Ballanger, PhD · 472138978 · benedicte.ballanger@cnrs.fr

Study locations

Site status can differ from overall study status. “Status not reported” means local availability needs confirmation. Remote participation and travel arrangements must be checked with the team.

Hôpital Neurologique Pierre Wertheimer - Service de Neurologie

Bron, France

Recruiting

Chloé Laurencin, MD, PhD · 472118022 · chloe.laurencin@chu-lyon.fr

Chloé Laurencin, MD/PhD

Facility not reported

France

Status not reported

The original descriptions and participation rules come from the registry. Participation is voluntary and does not guarantee benefit.